Tanta University
Tanta, El-Gharbia, 31527, Egypt
NCT Number: NCT07145840
This study aimed to; -
1. Study suicidal behavior among sample of schizophrenic patients. 2. Study relation between schizophrenic symptoms and suicidal behavior. 3. Study the relation of mood symptoms in schizophrenic patients and suicidal behavior.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Observational
Tanta, El-Gharbia, 31527, Egypt
Suicide is a major public health concern. According to the World Health Organization (WHO), approximately one million people die by suicide each year worldwide. This statistic means that every 40 seconds, someone dies by suicide somewhere on the globe, with many more people making non-lethal suicide attempts. It has been suggested that the number of individuals who attempt suicide without causing death is about 10-15 times the number of those who die by suicide.
Schizophrenia is a severe psychiatric disorder characterized by cognitive impairment and behavioral dysfunction. Patients with schizophrenia are at an elevated risk of self-harm, suicide, and all-cause mortality, which results in a reduction of life expectancy of up to 20 years compared with the general population.
Suicide risk in schizophrenia is notably high, and early detection depends on recognizing and evaluating clinical manifestations of depression, despair, and hopelessness, as well as the nature and severity of the psychotic experience, particularly in recently diagnosed patients with higher cognitive function and educational backgrounds.
There is a lack of studies on suicidal behaviors in schizophrenic patients in Arab countries. A study on overall suicidality in Arab countries reported a lifetime suicide attempt rate of 0.72%-6.3% and a suicide ideation rate of 2.09%-13.9%. More research is needed in this area due to the societal and economic costs of suicidal behavior in schizophrenic patients. This issue is a high priority for public health. Several trials have aimed to identify valid predictors of suicide risk. These predictors could not only help reduce the mortality associated with suicidality but also enable a more rational allocation of resources for treatment. Previous suicide attempts, depressive symptoms, hopelessness, and akathisia have been identified as reliable predictors of suicidal behavior.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Psychiatric interview for diagnosis of schizophrenia by SCID 5 (American Psychiatric Association, 2015), The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) is a semi structured interview guide for making the major DSM-5 diagnoses using the chapter of schizophrenia spectrum
Time frame: Within 1 week prior to assessment
Assessed using the Arabic version of the Beck Scale for Suicide Ideation (BSS), which includes 21 statement groups rated on a 3-point scale. The total score ranges from 0 to 38, with higher scores indicating more severe suicidal ideation.
Time frame: Within 7 days
Measured using the Positive and Negative Syndrome Scale (PANSS), which assesses positive, negative, and general psychopathology symptoms. Higher scores reflect greater symptom severity.
Time frame: Within 7 days
Measured using the Arabic version of the Hamilton Depression Rating Scale (HDRS-17). Total scores classify depression as mild, moderate, severe, or very severe.
Tanta University
Other
A Study of Suicidal Behavior Among Schizophrenic Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07603986
Anger, Behavior
Petah Tikva, Israel
View Trial DetailsNCT05656781
Behavior, Behavioral Symptoms
Hamilton, Canada
View Trial DetailsNCT07165561
Behavior, Behavioral Symptoms
Ghent, Belgium
View Trial DetailsNCT04565834
Inflammation, Pathologic Processes
Nîmes, Gard, France
View Trial Details